TY - JOUR AU - Kwon, Daniel Hyuck-Min AU - Friedlander, Terence PY - 2019 TI - A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer JF - Annals of Translational Medicine; Vol 7, Supplement 8 (December 31, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Metastatic prostate cancer, which presents as either de novo (4–5% of cases) or as a recurrence following definitive therapy for localized disease, has historically been treated with androgen deprivation therapy (ADT) alone. Although 90% of men initially respond to ADT, almost all eventually become castration-resistant and develop progression of their disease. UR - https://atm.amegroups.org/article/view/29150